IMM.L
現在値
5.30GBp変化
-0.58(-9.86%)出来高
1,479,299本日のレンジ
-
5.8252週レンジ
-
10.90∙ 約20分前の相場を表示しています。
前日終値 | 5.88 |
|---|---|
始値 | 5.82 |
出来高 | 1,479,299 |
3か月平均出来高 | 34.08 |
高値 | 5.82 |
安値 | 5.30 |
52週高値 | 10.90 |
52週安値 | 4.80 |
発行済株式数 | 284.98 |
時価総額 | 16.76 |
予想PER | -2.02 |
配当利回り | -- |
Immupharma Plc Announces Collaboration With Imperial College London
Immupharma H1 Diluted Loss Per Share 1.46 Pence Vs. 1.69 Pence Loss Year Ago
Immupharma Says CEO Dimitri Dimitriou To Step Down From The Role
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
業種
Business Services
エグゼクティブリーダーシップ
Timothy McCarthy
Non-Executive Chairman of the Board, Interim Chief Executive Officer
Timothy Gary Franklin
Chief Operating Officer, Director
Ewa Flynn
Company Secretary
Franco Di Muzio
Senior Non-Executive Independent Director
株価売上高倍率（過去12カ月） | -- |
|---|---|
株価売上高倍率（過去12カ月） | 190.44 |
株価純資産倍率（四半期） | 2.77 |
株価キャッシュフロー倍率 | -- |
総負債／総資本（四半期） | 12.36 |
長期負債／資本（四半期） | 0.00 |
投資利益率(過去12カ月） | -118.23 |
自己資本利益率（過去12カ月) | -100.38 |
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。